美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Tema GLP-1, Obesity & Cardiometabolic ETF

27.98

-0.2900-1.03%

盤後：28.080.1000+0.36%16:04 EDT

成交量：3,247.00

成交額：9.12萬

市值：4,980.44萬

市盈率：- -

高：28.37

開：28.37

低：27.98

收：28.27

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

從熱潮到低谷：減肥藥物市場的投資前景

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/HRTS"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HRTS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HRTS\",,,,,undefined,":{"symbol":"HRTS","market":"US","secType":"STK","nameCN":"Tema GLP-1, Obesity & Cardiometabolic ETF","latestPrice":27.98,"timestamp":1750449600000,"preClose":28.27,"halted":0,"volume":3247,"hourTrading":{"tag":"盘后","latestPrice":28.08,"preClose":27.98,"latestTime":"16:04 EDT","volume":2,"amount":55.96,"timestamp":1750449849065},"delay":0,"floatShares":1780000,"shares":1780000,"eps":0,"marketStatus":"休市中","change":-0.29,"latestTime":"06-20 16:00:00 EDT","open":28.37,"high":28.37,"low":27.98,"amount":91208.5099,"amplitude":0.013796,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":28.27,"sharesOutstanding":1780000,"nav":28.23,"aum":50249400,"dividendRate":0.016798,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.08,"preClose":27.98,"latestTime":"16:04 EDT","volume":2,"amount":55.96,"timestamp":1750449849065},"volumeRatio":0.9036513741162969,"impliedVol":0.1001,"impliedVolPercentile":0.28},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HRTS\",,,,,undefined,":{"symbol":"HRTS","floatShares":1780000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.9036513741162969,"shares":1780000,"dividePrice":0.47,"high":28.37,"amplitude":0.013796,"preClose":28.27,"low":27.98,"week52Low":25.3192,"pbRate":"--","week52High":36.03,"institutionHeld":0,"latestPrice":27.98,"eps":0,"divideRate":0.016798,"volume":3247,"delay":0,"ttmEps":0,"open":28.37,"prevYearClose":28.87,"prevWeekClose":28.81,"prevMonthClose":27.78,"prevQuarterClose":29.33,"fiveDayClose":29.19,"twentyDayClose":27.46,"sixtyDayClose":29.95},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/HRTS\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HRTS\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2494090371","title":"從熱潮到低谷：減肥藥物市場的投資前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2494090371","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494090371?lang=zh_tw&edition=fundamental","pubTime":"2024-12-25 14:00","pubTimestamp":1735106414,"startTime":"0","endTime":"0","summary":"近年来，减肥药物市场一度成为投资者关注的焦点，随着Novo Nordisk的Wegovy和Eli Lilly的Zepbound等药物的推出，投资者看到了巨大的增长潜力。2025年，减肥药物市场的走向将取决于供应量的增加、新一代药物的临床进展以及有关药品定价和GLP-1药物使用的监管清晰度。减肥药市场的竞争加剧Novo和Lilly已经在生产能力和市场份额方面展开了激烈竞争，但这种竞争并不仅限于大药企。Amgen在上个月宣布，其实验药物MariTide帮助患者减掉了20%的体重。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/25140046788428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["HRTS"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HRTS\",params:#limit:5,,,undefined,":[{"date":"2024-12-11","symbol":"HRTS","amount":0.46931,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-11","defaultRemindTime":1733927400000,"name":"Tema Cardiovascular and Metabolics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-12","payableDate":"2024-12-11","currency":"USD","dateTimestamp":1733893200000,"payDate":"2024-12-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HRTS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-11","recordDate":"2024-12-11","paymentDate":"2024-12-12","value":0.46931,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HRTS\",market:\"US\",delay:false,,,undefined,":{}}}